1
|
Le Solliec MA, Arabo A, Takhlidjt S, Maucotel J, Devère M, Berrahmoune H, Bénani A, Nedelec E, Lefranc B, Leprince J, Picot M, Chartrel N, Prévost G. Interactions between the regulatory peptide 26RFa (QRFP) and insulin in the regulation of glucose homeostasis in two complementary models: The high fat 26RFa-deficient mice and the streptozotocin insulin-deficient mice. Neuropeptides 2023; 98:102326. [PMID: 36791581 DOI: 10.1016/j.npep.2023.102326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/21/2022] [Revised: 01/18/2023] [Accepted: 02/02/2023] [Indexed: 02/11/2023]
Abstract
The regulatory peptide 26RFa (QRFP) is involved in the control of glucose homeostasis at the periphery by acting as an incretin, and in the brain by mediating the central antihyperglycemic effect of insulin, indicating the occurrence of a close relationship between 26RFa and insulin in the regulation of glucose metabolism. Here, we investigated the physiological interactions between 26RFa and insulin in two complementary models i.e. a model of obese/hyperglycemic mice deficient for 26RFa and a model of diabetic mice deficient for insulin. For this, transgenic 26RFa-deficient mice were made obese and chronically hyperglycemic by a 3-month high fat diet (HFD) and second group of mice was made diabetic by destruction of the β cells of the pancreatic islets using a single injection of streptozotocin. Our data reveal that 26RFa deficiency does not impact significantly the "glycemic" phenotype of the HFD mice. The pancreatic islets, liver, white adipose tissue masses are not altered by the lack of 26RFa production but the brown adipose tissue (BAT) weight is significantly increased in these animals. In diabetic insulin-deficient mice, the injection of 26RFa does not exhibit any beneficial effect on the impaired glucose homeostasis characterizing this model. Finally, we show that streptozotocin diabetic mice display lowered plasma 26RFa levels as compared to untreated mice, whereas the expression of the peptide in the duodenum is not affected. Taken together, the present results indicate that dysregulation of glucose homeostasis in obese/hyperglycemic mice is not aggravated by the absence of 26RFa that may be compensated by the increase of BAT mass. In diabetic insulin-deficient mice, the antihypergycemic effect of 26RFa is totally blunted probably as a result of the impaired insulin production characterizing this model, avoiding therefore the action of the peptide.
Collapse
Affiliation(s)
| | - Arnaud Arabo
- Univ Rouen Normandie, INSERM US 31, CNRS UAR 2026, HeRacLeS, F-76000 Rouen, France
| | - Saloua Takhlidjt
- Univ Rouen Normandie, INSERM UMR 1239, NorDiC, F-76000 Rouen, France
| | - Julie Maucotel
- Univ Rouen Normandie, INSERM US 31, CNRS UAR 2026, HeRacLeS, F-76000 Rouen, France
| | - Mélodie Devère
- Univ Rouen Normandie, INSERM UMR 1239, NorDiC, F-76000 Rouen, France
| | - Hind Berrahmoune
- Univ Rouen Normandie, INSERM UMR 1239, NorDiC, F-76000 Rouen, France
| | - Alexandre Bénani
- Center for Taste and Feeding Behaviour, CNRS (UMR6265), INRA (UMR1324), AgroSup Dijon, Université de Bourgogne-Franche Comté, 21000 Dijon, France
| | - Emmanuelle Nedelec
- Center for Taste and Feeding Behaviour, CNRS (UMR6265), INRA (UMR1324), AgroSup Dijon, Université de Bourgogne-Franche Comté, 21000 Dijon, France
| | - Benjamin Lefranc
- Univ Rouen Normandie, INSERM UMR 1239, NorDiC, F-76000 Rouen, France; Univ Rouen Normandie, Cell Imaging Platform of Normandy (PRIMACEN), F-76000 Rouen, France
| | - Jérôme Leprince
- Univ Rouen Normandie, INSERM UMR 1239, NorDiC, F-76000 Rouen, France; Univ Rouen Normandie, Cell Imaging Platform of Normandy (PRIMACEN), F-76000 Rouen, France
| | - Marie Picot
- Univ Rouen Normandie, INSERM UMR 1239, NorDiC, F-76000 Rouen, France
| | - Nicolas Chartrel
- Univ Rouen Normandie, INSERM UMR 1239, NorDiC, F-76000 Rouen, France.
| | - Gaëtan Prévost
- Normandie Univ, UNIROUEN, Inserm U1239, CHU Rouen, Department of Endocrinology, Diabetes and metabolic diseases, F-76000 Rouen, France
| |
Collapse
|
2
|
El Mehdi M, Takhlidjt S, Devère M, Arabo A, Le Solliec MA, Maucotel J, Bénani A, Nedelec E, Duparc C, Lefranc B, Leprince J, Anouar Y, Prévost G, Chartrel N, Picot M. The 26RFa (QRFP)/GPR103 neuropeptidergic system in mice relays insulin signalling into the brain to regulate glucose homeostasis. Diabetologia 2022; 65:1198-1211. [PMID: 35476025 DOI: 10.1007/s00125-022-05706-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/07/2022] [Accepted: 03/21/2022] [Indexed: 11/03/2022]
Abstract
AIMS/HYPOTHESIS 26RFa (pyroglutamilated RFamide peptide [QRFP]) is a biologically active peptide that regulates glucose homeostasis by acting as an incretin and by increasing insulin sensitivity at the periphery. 26RFa is also produced by a neuronal population localised in the hypothalamus. In this study we investigated whether 26RFa neurons are involved in the hypothalamic regulation of glucose homeostasis. METHODS 26Rfa+/+, 26Rfa-/- and insulin-deficient male C57Bl/6J mice were used in this study. Mice received an acute intracerebroventricular (i.c.v.) injection of 26RFa, insulin or the 26RFa receptor (GPR103) antagonist 25e and were subjected to IPGTTs, insulin tolerance tests, acute glucose-stimulated insulin secretion tests and pyruvate tolerance tests (PTTs). Secretion of 26RFa by hypothalamic explants after incubation with glucose, leptin or insulin was assessed. Expression and quantification of the genes encoding 26RFa, agouti-related protein, the insulin receptor and GPR103 were evaluated by quantitative reverse transcription PCR and RNAscope in situ hybridisation. RESULTS Our data indicate that i.c.v.-injected 26RFa induces a robust antihyperglycaemic effect associated with an increase in insulin production by the pancreatic islets. In addition, we found that insulin strongly stimulates 26Rfa expression and secretion by the hypothalamus. RNAscope experiments revealed that neurons expressing 26Rfa are mainly localised in the lateral hypothalamic area, that they co-express the gene encoding the insulin receptor and that insulin induces the expression of 26Rfa in these neurons. Concurrently, the central antihyperglycaemic effect of insulin is abolished in the presence of a GPR103 antagonist and in 26RFa-deficient mice. Finally, our data indicate that the hypothalamic 26RFa neurons are not involved in the central inhibitory effect of insulin on hepatic glucose production, but mediate the central effects of the hormone on its own peripheral production. CONCLUSION/INTERPRETATION We have identified a novel mechanism in the hypothalamic regulation of glucose homeostasis, the 26RFa/GPR103 system, and we provide evidence that this neuronal peptidergic system is a key relay for the central regulation of glucose metabolism by insulin.
Collapse
Affiliation(s)
- Mouna El Mehdi
- Inserm, U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université, UNIROUEN, Rouen, France
| | - Saloua Takhlidjt
- Inserm, U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université, UNIROUEN, Rouen, France
| | - Mélodie Devère
- Inserm, U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université, UNIROUEN, Rouen, France
| | - Arnaud Arabo
- Department of Biological Resources (SRB), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université, UNIROUEN, Rouen, France
| | - Marie-Anne Le Solliec
- Inserm, U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université, UNIROUEN, Rouen, France
| | - Julie Maucotel
- Department of Biological Resources (SRB), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université, UNIROUEN, Rouen, France
| | - Alexandre Bénani
- Centre for Taste and Feeding Behaviour, CNRS (UMR6265), INRA (UMR1324), AgroSup Dijon, Université de Bourgogne Franche-Comté, Dijon, France
| | - Emmanuelle Nedelec
- Centre for Taste and Feeding Behaviour, CNRS (UMR6265), INRA (UMR1324), AgroSup Dijon, Université de Bourgogne Franche-Comté, Dijon, France
| | - Céline Duparc
- Inserm, U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université, UNIROUEN, Rouen, France
| | - Benjamin Lefranc
- Inserm, U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université, UNIROUEN, Rouen, France
- Cell Imaging Platform of Normandy, Normandie Université, Rouen, France
| | - Jérôme Leprince
- Inserm, U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université, UNIROUEN, Rouen, France
- Cell Imaging Platform of Normandy, Normandie Université, Rouen, France
| | - Youssef Anouar
- Inserm, U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université, UNIROUEN, Rouen, France
| | - Gaëtan Prévost
- Inserm, U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université, UNIROUEN, Rouen, France
- Department of Endocrinology, Diabetes and Metabolic Diseases, Normandie Université, UNIROUEN, Rouen University Hospital, Rouen, France
| | - Nicolas Chartrel
- Inserm, U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université, UNIROUEN, Rouen, France.
| | - Marie Picot
- Inserm, U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université, UNIROUEN, Rouen, France
| |
Collapse
|
3
|
Le Solliec MA, Arabo A, Takhlidjt S, Maucotel J, Devère M, Riancho J, Berrahmoune H, do Rego JL, do Rego JC, Bénani A, Nedelec E, Lefranc B, Leprince J, Anouar Y, Picot M, Chartrel N, Prévost G. Acute but Not Chronic Central Administration of the Neuropeptide 26RFa (QRFP) Improves Glucose Homeostasis in Obese/Diabetic Mice. Neuroendocrinology 2022; 112:1104-1115. [PMID: 35093951 DOI: 10.1159/000522287] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Accepted: 01/23/2022] [Indexed: 11/19/2022]
Abstract
INTRODUCTION The aim of the study is to investigate whether acute or chronic central administration of the hypothalamic neuropeptide 26RFa may ameliorate the glycemic control of obese/diabetic mice. METHODS Mice were treated for 4 months with a high-fat (HF) diet and received a single i.c.v. injection of 26RFa (3 µg) or a chronic i.c.v. administration of the peptide during 28 days via osmotic minipumps (25 µg/day). i.p. and oral glucose (GLU) tolerance tests, insulin (INS) tolerance test, glucose-stimulated insulin secretion (GSIS), food/water intake, horizontal/vertical activity, energy expenditure, meal pattern, and whole-body composition were monitored. In addition, 26RFa and GPR103 mRNA expressions as well as plasma 26RFa levels were evaluated by RT-QPCR and radioimmunoassay. RESULTS Acute administration of 26RFa in HF mice induced a robust antihyperglycemic effect by enhancing INS secretion, whereas chronic administration of the neuropeptide is unable to improve glucose homeostasis in these obese/diabetogenic conditions. By contrast, chronic 26RFa treatment induced an increase of the body weight accompanied with an enhanced food intake and a decreased energy expenditure. Finally, we show that the HF diet does not alter the hypothalamic expression of the 26RFa/GPR103 neuropeptidergic system nor the levels of circulating 26RFa. CONCLUSION Our data indicate that the central beneficial effect of 26RFa on glucose homeostasis, by potentiating GSIS, is preserved in HF mice. However, chronic administration of the neuropeptide is unable to balance glycemia in these pathophysiological conditions, suggesting that the hypothalamic 26RFa/GPR103 neuropeptidergic system mainly affects short-term regulation of glucose metabolism.
Collapse
Affiliation(s)
- Marie-Anne Le Solliec
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
| | - Arnaud Arabo
- Institute for Research and Innovation in Biomedicine (IRIB), Department of Biological Resources (SRB), UNIROUEN, Normandie University, Rouen, France
| | - Saloua Takhlidjt
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
| | - Julie Maucotel
- Institute for Research and Innovation in Biomedicine (IRIB), Department of Biological Resources (SRB), UNIROUEN, Normandie University, Rouen, France
| | - Mélodie Devère
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
| | - Julien Riancho
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
| | - Hind Berrahmoune
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
| | - Jean-Luc do Rego
- Institute for Research and Innovation in Biomedecine (IRIB), UNIROUEN, Animal Behaviour Platform SCAC, Normandie University, Rouen, France
| | - Jean-Claude do Rego
- Institute for Research and Innovation in Biomedecine (IRIB), UNIROUEN, Animal Behaviour Platform SCAC, Normandie University, Rouen, France
| | - Alexandre Bénani
- Center for Taste and Feeding Behaviour, CNRS (UMR6265), INRA (UMR1324), AgroSup Dijon, Université de Bourgogne-Franche Comté, Dijon, France
| | - Emmanuelle Nedelec
- Center for Taste and Feeding Behaviour, CNRS (UMR6265), INRA (UMR1324), AgroSup Dijon, Université de Bourgogne-Franche Comté, Dijon, France
| | - Benjamin Lefranc
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
- Cell Imaging Platform of Normandy, Normandie University, Rouen, France
| | - Jérôme Leprince
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
- Cell Imaging Platform of Normandy, Normandie University, Rouen, France
| | - Youssef Anouar
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
| | - Marie Picot
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
| | - Nicolas Chartrel
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
| | - Gaëtan Prévost
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
- Department of Endocrinology, UNIROUEN, Rouen University Hospital, Diabetes and Metabolic Diseases, Normandie University, Rouen, France
| |
Collapse
|
4
|
El-Mehdi M, Takhlidjt S, Khiar F, Prévost G, do Rego JL, do Rego JC, Benani A, Nedelec E, Godefroy D, Arabo A, Lefranc B, Leprince J, Anouar Y, Chartrel N, Picot M. Glucose homeostasis is impaired in mice deficient in the neuropeptide 26RFa (QRFP). BMJ Open Diabetes Res Care 2020; 8:8/1/e000942. [PMID: 32114486 PMCID: PMC7050347 DOI: 10.1136/bmjdrc-2019-000942] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2019] [Revised: 01/09/2020] [Accepted: 01/28/2020] [Indexed: 11/03/2022] Open
Abstract
INTRODUCTION 26RFa (pyroglutamyl RFamide peptide (QRFP)) is a biologically active peptide that has been found to control feeding behavior by stimulating food intake, and to regulate glucose homeostasis by acting as an incretin. The aim of the present study was thus to investigate the impact of 26RFa gene knockout on the regulation of energy and glucose metabolism. RESEARCH DESIGN AND METHODS 26RFa mutant mice were generated by homologous recombination, in which the entire coding region of prepro26RFa was replaced by the iCre sequence. Energy and glucose metabolism was evaluated through measurement of complementary parameters. Morphological and physiological alterations of the pancreatic islets were also investigated. RESULTS Our data do not reveal significant alteration of energy metabolism in the 26RFa-deficient mice except the occurrence of an increased basal metabolic rate. By contrast, 26RFa mutant mice exhibited an altered glycemic phenotype with an increased hyperglycemia after a glucose challenge associated with an impaired insulin production, and an elevated hepatic glucose production. Two-dimensional and three-dimensional immunohistochemical experiments indicate that the insulin content of pancreatic β cells is much lower in the 26RFa-/- mice as compared with the wild-type littermates. CONCLUSION Disruption of the 26RFa gene induces substantial alteration in the regulation of glucose homeostasis, with in particular a deficit in insulin production by the pancreatic islets. These findings further support the notion that 26RFa is an important regulator of glucose homeostasis.
Collapse
|
5
|
Nedelec E, Giraud V, Tubiana S, Gomis T, Beauchet A, Chinet T. Formation des médecins généralistes à la spirométrie pour le dépistage de la BPCO : étude pilote. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.10.478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
6
|
Jouzeau JY, Pacquelet S, Boileau C, Nedelec E, Presle N, Netter P, Terlain B. Nitric oxide (NO) and cartilage metabolism: NO effects are modulated by superoxide in response to IL-1. Biorheology 2002; 39:201-14. [PMID: 12082283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
Nitric oxide (NO) is thought to mediate most effects of interleukin-1 (IL-1) on cartilage. In vitro evidence includes the decreased synthesis of extracellular matrix components, the abnormal cell renewal, the decreased production of IL-1 receptor antagonist, the induction of apoptosis and the enhanced sensitivity of chondrocytes to oxidative stress. Studies in NOS2(-/-) mice or administration of NO synthase inhibitors in animal models of joint disorders have confirmed its potent pathophysiological role in cartilage. Using L-NMMA (1 mM), as a NO synthase inhibitor, and CuDips (10 microM), as a SOD mimetic, we provide evidence that the inhibitory potency of IL-1beta on proteoglycan synthesis and its stimulating effect on COX-2 activity depend both on NO and O2-* production. Peroxynitrite formation is further demonstrated by the occurrence of 3-nitrotyrosines in chondrocytes stimulated in vitro with 2.5 ng/ml IL-1 and in femoral condyles of rats injected locally with 1 microg IL-1. Preliminary data suggest that such contribution of reactive oxygen species is not shared in common by IL-17, another NO-producing cytokine. We conclude that superoxide is a key modulator of NO-mediated effects in chondrocyte stimulated with IL-1 and that a combined therapy with NO synthase inhibitors and antioxidants may be promising for a full cartilage protection.
Collapse
Affiliation(s)
- Jean-Yves Jouzeau
- Laboratoire de Pharmacologie et UMR 7561 CNRS-UHP, Faculté de Médecine, Vandoeuvre-lès-Nancy, France.
| | | | | | | | | | | | | |
Collapse
|